Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

Autor: Jeitany, Maya, Leroy, Cédric, Tosti, Priscillia, Lafitte, Marie, Le Guet, Jordy, Simon, Valérie, Bonenfant, Debora, Robert, Bruno, Grillet, Fanny, Mollevi, Caroline, El Messaoudi, Safia, Otandault, Amaëlle, Canterel-Thouennon, Lucile, Busson, Muriel, Thierry, Alain R, Martineau, Pierre, Pannequin, Julie, Roche, Serge, Sirvent, Audrey

Publikováno v: EMBO Molecular Medicine
EMBO Molecular Medicine, Wiley Open Access, 2018, 10 (4), pp.e7918. ⟨10.15252/emmm.201707918⟩
EMBO Molecular Medicine, 2018, 10 (4), pp.e7918. ⟨10.15252/emmm.201707918⟩

International audience; The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion in vitro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f1c351b5f21a68cd6fc306982317e24d
https://hal.archives-ouvertes.fr/hal-01872978